|
See related Hydrea cap information |
|
|
|
Manufacturer |
Bristol-Myers Squibb |
|
Distributor |
DKSH |
|
Contents |
Hydroxyurea |
|
Indications |
Melanoma, resistant chronic myelocytic leukemia & recurrent, metastatic or inoperable carcinoma of the ovary. Used concomitantly w/ irradiation therapy in primary squamous cell (epidermoid) carcinomas of the head & neck (excluding the lip) & carcinoma of the cervix. |
|
Dosage |
Solid tumors Continuous therapy: 20-30 mg/kg daily as a single dose. Intermittent therapy: 80 mg/kg as single doses given every 3rd day. Carcinoma of the head, neck & cervix Concomitant therapy w/ irradiation: 80 mg/kg in single doses given every 3rd day. Resistant chronic myelocytic leukemia Continuous therapy: 20-30 mg/kg daily as a single dose. |
|
Contraindications |
Marked leucopenia, thrombocytopenia, severe anemia. |
|
Special Precautions |
Renal dysfunction. Monitor uric acid & blood cells levels. |
|
Adverse Drug Reactions |
Bone marrow suppression; rarely, GI disorders, skin rash, headache, disorientation, pulmonary edema, dysuria, renal tubular function impairment.
View ADR Monitoring Form |
|
Drug Interactions |
Live vaccines, chloramphenicol.
View more drug interactions with Hydrea |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Hydrea capsule |
|
|
|
Manufacturer: |
Bristol-Myers Squibb |
|
Distributor: |
DKSH |
|
|
|
|
